Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

South Korea says AstraZeneca, Pfizer COVID-19 vaccines 87% effective after first shot

Published 05/05/2021, 01:55 AM
Updated 05/05/2021, 02:00 AM
© Reuters. FILE PHOTO: A health worker gets a dose of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine at a COVID-19 vaccination center in Seoul, South Korea, March 10, 2021.  REUTERS/Kim Hong-Ji

By Hyonhee Shin

SEOUL (Reuters) - One dose of COVID-19 vaccines from AstraZeneca (NASDAQ:AZN) Plc and Pfizer (NYSE:PFE) was 86.6% effective in preventing infections among people aged 60 and older, real world data released by South Korea showed on Wednesday.

Data by the Korea Disease Control and Prevention Agency (KDCA) showed the Pfizer vaccine, jointly developed by BioNTech, was 89.7% effective in preventing infection at least two weeks after a first dose was given, while the AstraZeneca shot was 86.0% effective.

Its analysis is based on more than 3.5 million people in South Korea aged 60 and older for two months from Feb. 26 and included 521,133 people who received a first dose of either Pfizer or AstraZeneca shot.

There were 1,237 COVID-19 cases in the data and only 29 were from the vaccinated group, the KDCA said.

"It is shown that both vaccines provide a high protection against the disease after the first dose. (People) should get full vaccinations according to recommended schedule, as the protection rate will go up further after a second dose," it said.

The findings come as South Korea seeks to drum up participation in its immunisation drive after reports about potential safety issues discouraged some people from getting vaccinated.

"Around 95% of people who died from the coronavirus in our country were senior citizens aged 60 or older, and the vaccines will sharply lower risks for those people," health ministry official Yoon Tae-ho told a briefing on Wednesday.

Yoon said the possibility of side effects including blood clotting are "extremely low" and they are mostly curable.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

South Korea has so far vaccinated 6.7% of its 52 million strong population, but has set an ambitious target of giving shots to 70% of its people by September and reaching herd immunity by November.

Starting on Wednesday, South Koreans who are fully vaccinated and show a negative COVID-19 test and no symptoms will be exempted from the two-week mandatory quarantine upon their return from overseas travel, to encourages more vaccinations.

The KDCA reported 676 new COVID-19 cases as of midnight on Tuesday, bringing the country's total infections to 124,945, with 1,847 deaths.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.